Dendreon Posts Wider Than Expected Q4 Loss, But Revenues Up YoY (DNDN)

cancer, ceo, dendreon, disease, dndn, earnings, eps, health, income, loss, market, medical, mitchell gold, nasdaq, patients, quarter, revenues, shares, stock

Dendreon (NASDAQ:DNDN) reported Q4 and FY 2010 earnings results Tuesday during the trading day, posting a disappointing loss of $0.64 per share for the quarter, a bigger loss than the $0.49 analysts were projecting on average. Net loss for the year was $439.5 million, or $3.18 per share versus a loss of $2.04 per share in 2009.

Revenue for the quarter was $25 million, compared to $21,000 for the same quarter in 2009. FY revenue came in at $48.1 million, compared to $100,000 the year before.

Mitchell H. Gold, M.D., president and chief executive officer, said, "As we look to 2011, it will be a year of both execution and a year of growth for Dendreon, all of which is designed with a single goal in mind: to help patients with cancer live longer and live better lives."

By Stephanie Shyu

Most Popular Video News